ReviewMolecular psychiatry2012
Pharmacogenetics in psychiatry: translating research into clinical practice.
Review in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02566057 (Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2016Pooled it
- Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing.BMC psychiatry · 2020Trial
- 5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men.Alcoholism, clinical and experimental research · 2014Trial
- Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index.NPJ digital medicine · 2025Article
- Providers' Use of Pharmacogenetic Testing to Inform Antidepressant Prescribing: Results of Qualitative Interviews.Psychiatric services (Washington, D.C.) · 2023Article
- Individual Prediction of Optimal Treatment Allocation Between Electroconvulsive Therapy or Ketamine using the Personalized Advantage Index.Research square · 2023Article
- Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population.European journal of clinical pharmacology · 2020Article
- Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.Molecular neuropsychiatry · 2020Review
- How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Frontiers in genetics · 2020Review
- Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.The American journal of psychiatry · 2019Article
- Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method.Frontiers in genetics · 2018Article
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.International journal of molecular sciences · 2017Review
- Development of a Diverse Learning Experience for Diverse Psychiatry Resident Needs: A Four-Year Biological Psychiatry Curriculum Incorporating Principles of Neurobiology, Psychopharmacology, and Evidence-Based Practice.Psychiatry investigation · 2017Article
- New Clinically Relevant Findings about Violence by People with Schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Review
- Article
- Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.Pharmacogenomics and personalized medicine · 2016Review
- Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Schizophrenia bulletin · 2015Article
- The Need for Vigilance in the Marketing of Genomic Tests in Psychiatry.The Journal of nervous and mental disease · 2015Article
- Genetics in child and adolescent psychiatry: methodological advances and conceptual issues.European child & adolescent psychiatry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pharmacogenetic/pharmacogenomic (PGx) approaches to psychopharmacology aim to identify clinically meaningful predictors of drug efficacy and/or side-effect burden. To date, however, PGx studies in psychiatry have not yielded compelling results, and clinical utilization of PGx testing in psychiatry is extremely limited. In this review, the authors provide a brief overview on the status of PGx studies in psychiatry, review the commercialization process for PGx tests and then discuss methodological considerations that may enhance the potential for clinically applicable PGx tests in psychiatry. The authors focus on design considerations that include increased ascertainment of subjects in the earliest phases of illness, discuss the advantages of drug-induced adverse events as phenotypes for examination and emphasize the importance of maximizing adherence to treatment in pharmacogenetic studies. Finally, the authors discuss unique aspects of pharmacogenetic studies that may distinguish them from studies of other complex traits. Taken together, these data provide insights into the design and methodological considerations that may enhance the potential for clinical utility of PGx studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.